Tokyo · Japan · Drug Manufacturers - General

Daiichi Sankyo Company, Limited 4568.T

Price ¥2,837Mkt cap 5,162 JPY bnReports in JPYData 2 Nov 2026

Value estimate · 50% DCF, 50% peers¥3,480+22.7%+22.7% vs ¥2,837

DCF (base)¥4,517+59.2% vs price · WACC 6.4%

Peers¥2,4343 peers · median EV/EBITDA 9.9x

Price implies-0.1%revenue growth a year; your case 10.4%

Chance worth more93%of 2,000 simulated outcomes

Scenario

drives the result

Scenario probabilities (%)

BearBaseBull

Use the probability-weighted DCF instead of the live scenario

Forecast drivers

Base case, %

Driver	FY27E	FY28E	FY29E	FY30E	FY31E
Revenue growthFY23–FY26 avg 18.5%
EBIT marginFY23–FY26 avg 12.8%
Tax rateFY23–FY26 avg 11.8%
D&A % of revenueFY23–FY26 avg 4.1%
Capex % of revenueFY23–FY26 avg 7.5%
Working capital % of revenue changeFY23–FY26 avg -11.3%

No usable consensus estimate: the first years start from history. The base case fades to 5.0% by year five; bear and bull sit 3 points of growth and 1.5 points of margin either side.

Discount rate

WACC build

JPY 10-year government bond yield (%)Estimate: US 10-year Treasury yield. Replace it with the JPY 10-year government bond yield.

Less: country default spread (%)0 when the bond above is default-free

Beta2 years, weekly vs Nikkei 225: 0.21 (R² 0.01)

Equity risk premium (%)Damodaran country risk table (January 2026), Japan, rating A1

Pre-tax cost of debt (%)starter: bond yield + 1.5 points

Terminal growth g (%)must stay below WACC

Risk-free rate: 4.93%
Cost of equity: 6.47%
Weight of equity: 94.5%
After-tax cost of debt: 5.64%
WACC: 6.43%

Result rules

set before you look

DCF weight (%)peers get 50%

Share price (JPY)Yahoo, 2 Nov 2026 (delayed)

Check before you rely on thisYahoo's consensus revenue growth (31%) looks inconsistent with the reported history, so the forecast starts from history instead.The risk-free rate is an estimate for JPY: enter the local 10-year government bond yield.

In plain English

The model's numbers as sentences. Every figure comes from the live data and your inputs, so the story changes when you change an input.

Priced for slower growth than it has delivered

Favourable
At today's price of ¥2,837, the market is pricing in revenue growth of about -0.1% a year for FY27E–FY31E, holding the rest of your base case. Daiichi Sankyo Company, Limited's revenue grew 18.4% a year between FY23 and FY26, so the price asks for less than it has delivered.
Favourable
Your base case assumes 10.4% revenue growth a year on average, more than the price implies, and values the shares at ¥4,517, 59% above today's price.
Favourable
If your base case comes true, the whole business would return about 8.5% a year at today's price, 2.1 percentage points more than the 6.4% a year the model requires (the WACC).
Context
About 36% of today's price pays for future growth. The other 64%, ¥1,818 a share, is what FY26 operating profit after tax is worth if it never grows.
Favourable
Across 2,000 simulated futures around your base case, the middle 80% of values runs from ¥2,996 to ¥7,794 a share, and 93% of them are worth more than today's price.
Favourable
Business health grade B (70 out of 100): looks mostly healthy, with 5 strengths and 1 red flag (top concern: low return on capital).

Educational, not investment advice. “Favourable” means the numbers lean in today's price's favour; “Caution” means the price asks a lot of the future.

Football field

Every valuation range side by side, against today's price and the value estimate. Per share, in JPY.

Show as table

Range	Low	Mid	High
DCF scenarios (bear to bull)	¥3,323	¥4,517	¥5,886
DCF sensitivity (WACC and g ±1 point)	¥2,949	¥4,517	¥10,478
Monte Carlo (middle 80% of 2,000 runs)	¥2,996	¥4,573	¥7,794
EV/EBITDA comps (25th to 75th percentile)	¥1,930	¥2,180	¥2,672
P/E comps (25th to 75th percentile)	¥2,398	¥2,688	¥3,194
Analyst targets (16 analysts, low to high)	¥2,750	¥4,021	¥5,200
52-week share price (trading range)	¥2,390	–	¥3,913

Business health

Is this a good, honest business, not just a cheap one? Published screens on the reported annual accounts (FY23–FY26), plus plain ratios. Screens, not verdicts: read the accounts before relying on any of them.

GradeB70 / 100

Grade B (70/100): looks mostly healthy, with 5 strengths and 1 red flag (top concern: low return on capital).

Piotroski F-score4 / 9nine tests of strength

Altman Z''4.45Safe zone · safe above 2.60

Beneish M-score–not enough data

Red flags 1

Low return on capital: ROCE was 7.3% in FY26, below 10%.

Strengths 5

Profit is backed by cash: operations produced 98% of reported profit over 4 years.
Comfortable balance sheet: Altman Z'' is 4.45, in the safe zone (above 2.60).
High return for shareholders: ROE was 15.8% in FY26.
Net cash: cash exceeds all borrowings by JPY 254 bn in FY26.
Steady growth: revenue rose in each of the last 3 years.

Cash conversion Good98%Operating cash flow ÷ net profit, FY23–FY26. 90% or more means profit is backed by cash.

Return on capital (ROCE) Weak7.3%EBIT ÷ (total assets − current liabilities), FY26. 15% or more is strong.

Return on equity Good15.8%Net profit ÷ average shareholders' equity, FY26. 15% or more is strong.

Interest cover Good28.7xEBIT ÷ interest cost, FY26. 5x or more is comfortable; below 2x is risky.

Net debt ÷ EBITDA GoodNet cashCash exceeds borrowings (including leases) by JPY 254 bn.

Receivable days n/a–Receivables not reported for two years.

Share count change Good−1.2% a yearWeighted diluted shares, a year, FY23–FY26. Above 2% a year is heavy dilution; shares issued for mergers count too.

Paid out to shareholders Info87.9%Dividends and buybacks ÷ net profit, FY23–FY26. Neither high nor low is good on its own: it depends on how well the company could reinvest.

Stock-based pay n/a–Stock-based compensation not reported.

Years of revenue growth Good3 of 3Years in which revenue beat the year before, FY23–FY26.

EBIT margin trend Good+1.4 ptsFrom 9.4% in FY23 to 10.8% in FY26.

Piotroski's tests, one by one (4 passed of 9)

PASS
Made a profit Return on assets 7.5% in FY26
A company that loses money on its assets is using up its owners' capital.
PASS
Operations brought in cash Operating cash flow JPY 77.7 bn in FY26
Profit has to arrive as cash in the end, and cash flow is harder to dress up than profit.
FAIL
Return on assets improved 7.5% vs FY25's 8.5%
Rising profitability is one of the clearest signs a business is getting stronger.
FAIL
Cash from operations beat profit Cash JPY 77.7 bn vs profit JPY 260 bn
When cash lags profit, earnings may rest on generous accounting or customers who pay late.
FAIL
Long-term debt fell relative to assets Long-term debt 8.0% of average assets vs FY25's 2.9%
More debt leaves less room for error when business slows.
FAIL
Short-term liquidity improved Current ratio 2.42 vs FY25's 2.53
More short-term assets per rupee of bills due within a year means less risk of a cash squeeze.
PASS
No new shares issued Diluted shares −2.4% vs FY25
Issuing shares shrinks each owner's slice and can mean the company could not fund itself.
FAIL
Gross margin improved Gross margin 68.5% vs FY25's 78.0%
A higher gross margin points to pricing power or falling costs.
PASS
Assets worked harder (turnover up) Revenue ÷ assets 0.61x vs FY25's 0.54x
More sales from the same assets means the business uses its capital better.

F-score by year: FY24 8/9 · FY25 6/9

How the Altman and Beneish scores are built

Altman Z'' = 4.45 (safe)
Ratio	Value	Weight	Adds
Working capital ÷ total assets	0.314	6.56	2.06
Retained earnings ÷ total assets	0.387	3.26	1.26
Operating profit (EBIT) ÷ total assets	0.057	6.72	0.38
Book equity ÷ total liabilities	0.711	1.05	0.75

FY26 figures. Safe above 2.60, grey zone 1.10 to 2.60, distress below 1.10.

Z'' by year: FY23 5.87 · FY24 5.47 · FY25 5.14

How to read this

Piotroski F-score (Joseph Piotroski, 2000): nine pass-or-fail tests of profitability, debt, liquidity and efficiency, each comparing the latest year with the one before. 7 or more is strong; 3 or fewer is weak.

Altman Z'' (Edward Altman, 1995, the version for non-manufacturers and emerging markets): combines working capital, retained earnings, operating profit and book equity relative to the balance sheet. Above 2.60 is the safe zone, below 1.10 the distress zone.

Beneish M-score (Messod Beneish, 1999): eight ratios that, in his study, separated companies later found to have manipulated earnings. Above −1.78 resembles that pattern. It is a prompt to read the notes to the accounts, not an accusation.

Grade: a 0 to 100 blend (Piotroski 40%, Altman 20%, Beneish 15%, the ratios 25%, re-weighted when a part is missing): A from 80, B from 65, C from 50, D from 35, E below.

All three screens were built on US companies and annual accounts from Yahoo Finance, which can be incomplete. Lenders, insurers and holding companies get financial-firm ratios instead of the Altman and Beneish screens.

Beneish M-score could not be computed: DSRI needs receivables, current assets, net property and equipment, total assets and operating cash flow for FY25 and FY26.
Not available from the data: receivable days, stock-based pay.

What analysts expect

Price targets and ratings from the brokers' analysts who cover the stock, as Yahoo collects them. Their opinion, not this app's; set against the model so you can see where you differ.

16 analysts' average 12-month target is ¥4,021, +41.7% against today's ¥2,837 (median ¥4,050). The range runs from ¥2,750 to ¥5,200.

Ratings this month: 13 buy, 3 hold, 0 sell; the average works out to "Strong buy" (1.5 on a 1 to 5 scale, 1 = strong buy).

Your value estimate of ¥3,480 is 13% below the analysts' average.

Targets are usually for 12 months ahead and tend to run optimistic; brokers that cover a company often do business with it. Counts and targets come from different updates, so they may not match exactly.

Risk and likely range

How much the shares have swung and how far they have fallen over five years. Risk repeats far more reliably than direction, so this is the honest kind of forecast: how far the price may move, not which way.

Loading five years of prices…

What the price implies

A reverse DCF: the constant revenue growth, or the constant EBIT margin, that makes the DCF equal today's price, holding everything else in your base case.

Implied revenue growth, a year-0.1%Your base case averages 10.4%. The market expects less growth than you do.

Implied EBIT margin7.0%Your base case averages 10.8%; the last reported year was 10.8%.

What you'd earn at today's price

The yearly return on the whole business at today's price if your base case comes true, against the return the model requires and what a government bond pays.

Favourable

If your base case comes true, today's price earns about 8.5% a year, 2.1 percentage points more than the 6.4% the model requires.

Expected returnif your base case comes true8.5%
Required return (WACC)what the model discounts at6.4%
Government bondwhat the JPY 10-year government bond pays4.9%

What the price pays for

Today's business, no growth64%¥1,818 a share: earnings power value

Future growth36%¥1,019 a share

Earnings yield5.8%¥165.11 trailing EPS ÷ price

Free cash flow yield3.0%FY27E forecast ÷ market value

10-year bond4.9%interest a year

Cost of equity6.5%what shareholders require

Favourable

Every ¥100 of share price buys ¥5.82 of today's profit a year, more than the ¥4.93 of interest the bond pays, though profit is less certain than interest.

How these are worked out

Expected return (an internal rate of return). Imagine buying the whole company at today's price: its shares and its debt, less its cash. The expected return is the yearly rate that makes the free cash flows in your base case, plus the value after FY31E growing at 3.0%, add up to exactly today's price. When it is above the WACC, the price sits below your DCF value. It only comes true if the forecast does.

Earnings power value. What the business is worth if its last reported operating profit never grows or shrinks (a simplified version of Bruce Greenwald's method). It treats depreciation as the spending needed to stand still, and uses reported rather than average profit, so one unusual year moves it.

FY26 operating profit (EBIT), JPY bn: 229
After tax at 11.8%: 202
Held flat for ever: ÷ WACC of 6.4%: 3,145
+ Cash − debt, leases, minorities and dividends since the balance sheet: 163
÷ Shares, per share: ¥1,818

Earnings yield is the profit a year you buy with each unit of price (the P/E turned upside down). Free cash flow yield is the same idea with next year's forecast cash flow.

Show as table

Measure	Value
Expected return (IRR), base case	8.5%
Required return (WACC)	6.4%
Expected minus required	+2.1 pts
Cost of equity	6.5%
10-year government bond	4.9%
Earnings power value per share	¥1,818
Share of price paying for growth	36%
Earnings yield	5.8%
Free cash flow yield	3.0%

Three scenarios

Revenue path for each scenario and its value per share with the same WACC and terminal growth.

Bear · 25%¥3,323+17.1% vs price

Base · 50%¥4,517+59.2% vs price

Bull · 25%¥5,886+107.5% vs price

Probability-weighted¥4,561+60.8% vs price

ReportedBearBaseBull

Show as table

Revenue, JPY bn	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E	FY30E	FY31E
Reported	1,278	1,602	1,886	2,123
Bear					2,452	2,668	2,841	2,963	3,023
Base					2,516	2,813	3,080	3,305	3,470
Bull					2,579	2,961	3,331	3,675	3,969

Monte Carlo

2,000 simulated futures around your base case. Each run shifts growth, margin, WACC and terminal growth at random using the spreads below (one standard deviation).

Growth spread (± pts)Margin spread (± pts)WACC spread (± pts)Terminal growth spread (± pts)

Worth more than the price93%of runs above ¥2,837

Median outcome¥4,573+61.2% vs price

Downside (10th pct)¥2,9961 run in 10 is lower

Upside (90th pct)¥7,7941 run in 10 is higher

Runs below today's priceRuns above it

Free cash flow, base case

FCF = EBIT × (1 − tax) + D&A − capex − increase in working capital, discounted at the WACC from today to each fiscal year end.

Free cash flowPresent value

JPY bn	FY27E	FY28E	FY29E	FY30E	FY31E
Revenue	2,516	2,813	3,080	3,305	3,470
EBIT	272	304	333	357	375
NOPAT = EBIT × (1 − tax)	240	268	293	315	331
+ D&A	103	115	126	135	142
− Capex	189	191	188	178	163
− Increase in working capital	0.00	0.00	0.00	0.00	0.00
Free cash flow	154	192	232	272	310
Present value	150	176	199	220	235
Years to year end (t)	0.41	1.41	2.41	3.41	4.41

From cash flows to a share price

Enterprise value plus cash, minus debt, leases, minority interests and cash already returned to shareholders since the balance sheet, divided by the shares.

Present value of FCF: 981
Present value of terminal value: 7,076
Enterprise value: 8,056
+ Cash and short-term investments (31 Mar 2026): 555
− Borrowings: 300
− Lease liabilities: 0.00
− Minority interests: 0.00
− Dividends since the balance sheet: 91.0
Equity value: 8,219
÷ Shares outstanding: 1,819.65 mn
Value per share: ¥4,517

All amounts in JPY bn. Dividends with ex-dates after 2026-03-31: 2026-09-29 (50.00 per share).

Terminal value share of enterprise value87.8%Above 75%: most of the value comes after the forecast years.

Sensitivity: WACC against terminal growth

DCF value per share, base case. Blue cells sit above today's price, red cells below; the outlined cell is your current pair.

g ↓ · WACC →	5.43%	5.93%	6.43%	6.93%	7.43%
2.0%	¥4,657	¥4,066	¥3,609	¥3,245	¥2,949
2.5%	¥5,366	¥4,586	¥4,005	¥3,556	¥3,198
3.0%	¥6,367	¥5,284	¥4,517	¥3,946	¥3,504
3.5%	¥7,889	¥6,269	¥5,204	¥4,449	¥3,887
4.0%	¥10,478	¥7,767	¥6,173	¥5,125	¥4,383

Peers

Found from Yahoo's related stocks in the same industry; multiples rebuilt here so currencies match. Untick a peer to drop it, or add your own.

Company	In median	EV/EBITDA	P/E	EV/Sales	P/B	Op. margin	Rev. growth
Chugai Pharmaceutical Co., Ltd. 4519.T Drug Manufacturers - General		14.7x	22.4x	7.4x	5.4x	50.1%	21.5%
Astellas Pharma Inc. 4503.T Drug Manufacturers - General		7.5x	12.8x	2.2x	2.4x	28.9%	26.7%
Otsuka Holdings Co., Ltd. 4578.T Drug Manufacturers - General		9.9x	16.3x	2.2x	2.0x	20.0%	11.3%
Median of included	3	9.9x	16.3x	2.2x	2.4x
Daiichi Sankyo Company, Limited	–	13.1x	17.2x	2.1x	3.1x	10.8%	12.6%

Add a peer

Implied value per share	25th pct	Median	75th pct
EV/EBITDA × EBITDA + net cash	¥1,930 (8.7x)	¥2,180 (9.9x)	¥2,672 (12.3x)
P/E × earnings per share	¥2,398 (14.5x)	¥2,688 (16.3x)	¥3,194 (19.3x)
P/B × book value per share	¥1,994 (2.2x)	¥2,193 (2.4x)	¥3,567 (3.9x)
EV/Sales × revenue + net cash (check only)	¥2,964 (2.2x)	¥2,988 (2.2x)	¥6,249 (4.8x)
Peer value (average of median EV/EBITDA and median P/E prices)		¥2,434

Against its own past

Is today's multiple high or low for this stock? Its P/E (price ÷ earnings per share) or P/B (price ÷ book value per share) month by month, against the range it has traded in.

Loading ten years of monthly prices…

Pitch summary

Three pieces of evidence that lead to a view. The client summary button copies all of this as text.

1 · Margins+1 bpsEBIT margin change from the last reported year (10.8%) to FY31E (10.8%)

2 · Valuation vs peers+32.2%Daiichi Sankyo Company, Limited EV/EBITDA against the peer median; negative means cheaper

3 · Cash3.0%FCF yield: FY27E free cash flow ÷ market value at today's price

Daiichi Sankyo Company, Limited (4568.T), valuation summary, 2 Nov 2026
Value estimate ¥3,480 (+22.7% vs today's price of ¥2,837).

• DCF (base case): ¥4,517 per share. WACC 6.43%, terminal growth 3.0%; terminal value is 88% of enterprise value.
• Peers: ¥2,434 per share (average of median EV/EBITDA and median P/E prices; 3 peers).
• Scenarios: bear ¥3,323, base ¥4,517, bull ¥5,886; probability-weighted ¥4,561.
• What the price implies: -0.1% revenue growth a year for FY27E–FY31E, against 10.4% in this forecast.
• Monte Carlo: 93% of 2,000 simulated outcomes are above today's price; middle 80% ¥2,996 to ¥7,794.
• Key assumptions (base): revenue growth 18.5% → 11.8% → 9.5% → 7.3% → 5.0%; EBIT margin 10.8% to 10.8%; tax 11.8%.
• Checks: to review: Terminal value is less than 85% of enterprise value.

Data: Yahoo Finance via yahoo-finance2 (unofficial; delayed prices), as of 2 Nov 2026. Educational model, not investment advice.

Model checks

6 pass, 1 to review.

PASSWACC is above terminal growth g
PASSThe DCF gives a positive value per share
PASSShares × price is within 2% of the reported market cap
PASSScenario values are in order: bear ≤ base ≤ bull
PASSAt least three peers are in the medians
CHECKTerminal value is less than 85% of enterprise valueMost of the value sits after year 5: check terminal growth and the year-5 margin.
PASSThe forecast starts after the last reported year

Company data

What the model uses, from Yahoo Finance via yahoo-finance2 (unofficial; delayed prices). Edit any number that looks wrong; your edits stay in this browser and are marked.

JPY bn	FY23	FY24	FY25	FY26	Avg ratio
Revenue					growth 18.5%
EBIT (operating profit)					margin 12.8%
D&A					4.1%
Profit before tax
Tax					rate 11.8%
Capex					7.5%
Increase in working capital					-11.3% of Δrev

Cash and short-term investments (JPY bn)
Borrowings (JPY bn)
Lease liabilities (JPY bn)
Minority interests (JPY bn)
Dividends since the balance sheet (JPY bn)

Revenue, trailing 12 months (JPY bn)
EBITDA, trailing 12 months (JPY bn)
Net income, trailing 12 months (JPY bn)
Shares outstanding (mn)

FY labels follow Indian fiscal years ending in March. Shares: 1,819,653,230. Price ¥2,837 at Mon, 02 Nov 2026 00:13:41 GMT.

Loading prices, five years of statements and peers…

The first visit to a stock takes a few seconds; repeat visits are cached.

Driver

FY27E

FY28E

FY29E

FY30E

FY31E

Revenue growthFY23–FY26 avg 18.5%

EBIT marginFY23–FY26 avg 12.8%

Tax rateFY23–FY26 avg 11.8%

D&A % of revenueFY23–FY26 avg 4.1%

Capex % of revenueFY23–FY26 avg 7.5%

Working capital % of revenue changeFY23–FY26 avg -11.3%

Range

Low

Mid

High

DCF scenarios (bear to bull)

¥3,323

¥4,517

¥5,886

DCF sensitivity (WACC and g ±1 point)

¥2,949

¥4,517

¥10,478

Monte Carlo (middle 80% of 2,000 runs)

¥2,996

¥4,573

¥7,794

EV/EBITDA comps (25th to 75th percentile)

¥1,930

¥2,180

¥2,672

P/E comps (25th to 75th percentile)

¥2,398

¥2,688

¥3,194

Analyst targets (16 analysts, low to high)

¥2,750

¥4,021

¥5,200

52-week share price (trading range)

¥2,390

–

¥3,913

Altman Z'' = 4.45 (safe)

Ratio

Value

Weight

Adds

Working capital ÷ total assets

0.314

6.56

2.06

Retained earnings ÷ total assets

0.387

3.26

1.26

Operating profit (EBIT) ÷ total assets

0.057

6.72

0.38

Book equity ÷ total liabilities

0.711

1.05

0.75

Measure

Value

Expected return (IRR), base case

8.5%

Required return (WACC)

6.4%

Expected minus required

+2.1 pts

Cost of equity

6.5%

10-year government bond

4.9%

Earnings power value per share

¥1,818

Share of price paying for growth

36%

Earnings yield

5.8%

Free cash flow yield

3.0%

Revenue, JPY bn

FY23

FY24

FY25

FY26

FY27E

FY28E

FY29E

FY30E

FY31E

Reported

1,278

1,602

1,886

2,123

Bear

2,452

2,668

2,841

2,963

3,023

Base

2,516

2,813

3,080

3,305

3,470

Bull

2,579

2,961

3,331

3,675

3,969

JPY bn

FY27E

FY28E

FY29E

FY30E

FY31E

Revenue

2,516

2,813

3,080

3,305

3,470

EBIT

272

304

333

357

375

NOPAT = EBIT × (1 − tax)

240

268

293

315

331

+ D&A

103

115

126

135

142

− Capex

189

191

188

178

163

− Increase in working capital

0.00

Free cash flow

154

192

232

272

310

Present value

150

176

199

220

235

Years to year end (t)

0.41

1.41

2.41

3.41

4.41

g ↓ · WACC →

5.43%

5.93%

6.43%

6.93%

7.43%

2.0%

¥4,657

¥4,066

¥3,609

¥3,245

¥2,949

2.5%

¥5,366

¥4,586

¥4,005

¥3,556

¥3,198

3.0%

¥6,367

¥5,284

¥4,517

¥3,946

¥3,504

3.5%

¥7,889

¥6,269

¥5,204

¥4,449

¥3,887

4.0%

¥10,478

¥7,767

¥6,173

¥5,125

¥4,383

Company

In median

EV/EBITDA

P/E

EV/Sales

P/B

Op. margin

Rev. growth

Chugai Pharmaceutical Co., Ltd. 4519.T

Drug Manufacturers - General

14.7x

22.4x

7.4x

5.4x

50.1%

21.5%

Astellas Pharma Inc. 4503.T

Drug Manufacturers - General

7.5x

12.8x

2.2x

2.4x

28.9%

26.7%

Otsuka Holdings Co., Ltd. 4578.T

Drug Manufacturers - General

9.9x

16.3x

2.2x

2.0x

20.0%

11.3%

Median of included

9.9x

16.3x

2.2x

2.4x

Daiichi Sankyo Company, Limited

–

13.1x

17.2x

2.1x

3.1x

10.8%

12.6%

Implied value per share

25th pct

Median

75th pct

EV/EBITDA × EBITDA + net cash

¥1,930 (8.7x)

¥2,180 (9.9x)

¥2,672 (12.3x)

P/E × earnings per share

¥2,398 (14.5x)

¥2,688 (16.3x)

¥3,194 (19.3x)

P/B × book value per share

¥1,994 (2.2x)

¥2,193 (2.4x)

¥3,567 (3.9x)

EV/Sales × revenue + net cash (check only)

¥2,964 (2.2x)

¥2,988 (2.2x)

¥6,249 (4.8x)

Peer value (average of median EV/EBITDA and median P/E prices)

¥2,434

Daiichi Sankyo Company, Limited (4568.T), valuation summary, 2 Nov 2026 Value estimate ¥3,480 (+22.7% vs today's price of ¥2,837). • DCF (base case): ¥4,517 per share. WACC 6.43%, terminal growth 3.0%; terminal value is 88% of enterprise value. • Peers: ¥2,434 per share (average of median EV/EBITDA and median P/E prices; 3 peers). • Scenarios: bear ¥3,323, base ¥4,517, bull ¥5,886; probability-weighted ¥4,561. • What the price implies: -0.1% revenue growth a year for FY27E–FY31E, against 10.4% in this forecast. • Monte Carlo: 93% of 2,000 simulated outcomes are above today's price; middle 80% ¥2,996 to ¥7,794. • Key assumptions (base): revenue growth 18.5% → 11.8% → 9.5% → 7.3% → 5.0%; EBIT margin 10.8% to 10.8%; tax 11.8%. • Checks: to review: Terminal value is less than 85% of enterprise value. Data: Yahoo Finance via yahoo-finance2 (unofficial; delayed prices), as of 2 Nov 2026. Educational model, not investment advice.

JPY bn

FY23

FY24

FY25

FY26

Avg ratio

Revenue

growth 18.5%

EBIT (operating profit)

margin 12.8%

D&A

4.1%

Profit before tax

Tax

rate 11.8%

Capex

7.5%

Increase in working capital

-11.3% of Δrev